US FDA to improve communication on risk:benefit issues
This article was originally published in RAJ Devices
The US Food and Drug Administration has developed a Strategic Plan for Risk Communication in its effort to provide healthcare professionals and consumers with more meaningful information about the benefits and risks of regulated products, ie drugs, medical devices, food and tobacco1,2.
You may also be interested in...
An independent audit of the new EU Clinical Trials Information System has finally commenced, indicating that plans are on track for the EU Clinical Trial Regulation to be implemented from December 2021.
EU regulators have agreed on supplementary pharmacovigilance requirements applicable to COVID-19 vaccines following approval.
The UK Medicines and Healthcare products Regulatory Agency wants clinical trial sponsors to integrate available regulatory flexibilities into normal practice so that their studies can withstand further potential disruptions from the COVID-19 pandemic.